Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Finland |
|---|---|
| Lista | Small Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Biohit Oyj Stock Exchange Release March 30, 2023 at 11:00 a.m. (EEST)
A total number of 68,000 new Biohit Plc B-shares have been subscribed for with stock options I 2021A and stock options I 2022A between 1 March 2023 and 17 Mach 2023. These shares have been entered into the Trade Register on March 30, 2023, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading begins on Nasdaq Helsinki Ltd as of Mach 31, 2023 together with the existing B-shares.
The share subscription price was EUR 1.00 per share respectively. The entire subscription price of EUR 68,000 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value.
After the subscriptions the number of all Biohit Plc's shares will rise to 15,113,593 shares and B-shares will rise to 12,138,093 shares.
The share subscription period with stock options I 2021A began on March 1, 2023 and ends on March 1, 2028 The option scheme is based on the Biohit Plc board resolution of December 7, 2021 and the Annual General Meeting authorization of September 16, 2020.
The share subscription period with stock options I 2022A began on March1, 2023 and ends on March 1, 2028. The option scheme is based on the Biohit Plc board resolution of November 28, 2022 and the Annual General Meeting authorization of June 15, 2022.
The terms and conditions of the option schemes with additional information are available on Biohit Plc website at www.biohithealthcare.com.
Additional information:
CEO Jussi Hahtela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T)